Cat. No.: HY-17412A

Minocycline

Name: Minocycline
Brand: MedChemExpress
SKU: HY-17412A
Price: 180.00 USD
Availability: InStock
Rating: 5 (76 reviews)

76 Cited Publications

Avis client

Based on 76 publication(s) in Google Scholar

Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 98.59%
CAS No.: 10118-90-8
Formule: C₂₃H₂₇N₃O₇
Masse moléculaire:457.48

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Minocycline Chemical Structure

CAS No.: 10118-90-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (76)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole (1)
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

L-type calcium channel

Voir tous les produits spécifiques à Isoform Antibiotic :

Voir tous les produits spécifiques à Isoform HIF/HIF Prolyl-Hydroxylase :

Voir tous les produits spécifiques à Isoform Calcium Channel :

Cellular Effect

Cell Line	Type	Value	Description	References
BV-2	IC₅₀	15 μM Compound: MINO	Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 20 hrs by Griess assay Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 20 hrs by Griess assay	[PMID: 33822610]
BV-2	IC₅₀	15.49 μM Compound: Minocycline	Inhibition of NO production in LPS-induced mouse BV-2 cells incubated for 24 hrs by Griess reagent based microplate reader analysis Inhibition of NO production in LPS-induced mouse BV-2 cells incubated for 24 hrs by Griess reagent based microplate reader analysis	[PMID: 37172474]
BV-2	IC₅₀	17.5 μM Compound: Minocycline	Ant-inflammatory LPS-induced mouse BV2 cells assessed as reduction in NO production after 24 hrs by Griess reagent based assay Ant-inflammatory LPS-induced mouse BV2 cells assessed as reduction in NO production after 24 hrs by Griess reagent based assay	[PMID: 32129063]
BV-2	IC₅₀	18.5 μM Compound: Minocycline	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess assay	[PMID: 32141299]
BV-2	IC₅₀	27.2 μM Compound: Minocycline	Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess assay Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess assay	[PMID: 31415170]
BV-2	IC₅₀	35.82 μM Compound: Minocycline	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 27919656]
BV-2	IC₅₀	37.04 μM Compound: Minocycline	Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction	[PMID: 27623545]
BV-2	IC₅₀	4.9 μM Compound: Minocycline	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay	[PMID: 30350995]
BV-2	IC₅₀	9.07 μM Compound: Minocycline	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
CCRF-CEM	CC₅₀	52.1 μM Compound: minocycline	Cytotoxicity against CEM cells after 5 days by MTT method Cytotoxicity against CEM cells after 5 days by MTT method	[PMID: 17376679]
CCRF-CEM	EC₅₀	>52.1 μM Compound: minocycline	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral-induced cytopathicity Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral-induced cytopathicity	[PMID: 17376679]
N9	IC₅₀	19.89 μM Compound: Minocycline	Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 28073678]
RAW264.7	IC₅₀	31.28 μM Compound: Minocycline	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS induced nitric oxide production preincubated for 2 hrs followed by LPS challenge measured after 24 hrs by Griess reagent based assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS induced nitric oxide production preincubated for 2 hrs followed by LPS challenge measured after 24 hrs by Griess reagent based assay	[PMID: 29853329]
RAW264.7	IC₅₀	34.81 μM Compound: MINO	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs	[PMID: 23391590]
RAW264.7	IC₅₀	34.85 μM Compound: MINO	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method	[PMID: 22264489]
RAW264.7	IC₅₀	55.1 μM Compound: Minocycline	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 27765508]

In Vitro

Minocycline (0-100 μM, 24-72 h) suppresses proliferation and clonogenic activity of ovarian cancer cell-lines (OVCAR-3, SKOV-3 and A2780)^[3].
Minocycline (0-100 μM, 24-48 h)arrests cell cycle through inhibition of cyclins and suppression of DNA incorporation^[3].
Minocycline (0-100 μM, 72 h) induces cell apoptosis in ovarian cancer cell lines^[3].
Minocycline shows direct neuronal protection, and this mode of protection is likely to be associated with the preservation of mitochondrial integrity and cytochrome c, followed by the suppression of caspase-dependent as well as caspase-independent cell death^[2].
Minocycline leads to suppression of Hypoxia-inducible factor (HIF)-1α accompanied by up-regulation of p53 protein levels and inactivation of AKT/mTOR/p70S6K/4E-BP1 pathway^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Proliferation Assay^[3]

View Protocol

Cell Line:

Human ovarian cancer cell lines (OVCAR-3, SKOV-3 and A2780) and primary cells (HEK-293, HMEC, HUVEC, ATCC)
Concentration:

0, 1, 10, 50 and 100 μM
Incubation Time:

24, 48 or 72 h
Result:

Inhibited proliferation of OVCAR-3, SKOV-3 and A2780 cells in a concentration-dependent manner, with IC₅₀ values of 62.0, 56.1 and 59.5 μM, respectively. Had no effect on the viability of HEK-293 or HUVEC.

Cell Cycle Analysis^[3]

View Protocol

Cell Line:

OVCAR-3, SKOV-3 and A2780 cells
Concentration:

0, 10, 50 and 100 μM
Incubation Time:

24 or 48 h
Result:

Arrested cells in the G0-G1 phase in a concentration and time-dependent manner. Declined percentage of cells in the S and G2-M phases in excess of 80% each at 100 μM.

Western Blot Analysis^[3]

View Protocol

Cell Line:

OVCAR-3, SKOV-3 and A2780 cells
Concentration:

0, 10, 50 and 100 μM
Incubation Time:

72 h
Result:

Expressed lower levels of cyclins A, B and E. Increased caspase-3 levels by more than 3.0 fold in the 100 μM. Minocycline-activated caspase-3 in turn led to cleavage of PARP-1. Increased the degradation product p89 of PARP-1 by caspase-3.

In Vivo

Minocycline (0-30 mg/kg, orally, daily for 4 weeks) suppresses OVCAR-3 tumor growth in female nude mice^[3].
Minocycline (IP) is an effective neuroprotective agent in animal models of cerebral ischemia when given in high doses intraperitoneally^[1].
Minocycline (0-40 mg/kg, IP, once) significantly attenuats METH-induced hyperlocomotion and the development of behavioral sensitization in mice^[2].
Minocycline (3 and 10 mg/kg, IV, once) is effective at reducing infarct size in a Temporary Middle Cerebral Artery Occlusion model (TMCAO)^[1].
Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. This effect may be associated with activations of PI3K/Akt signaling pathway, mitochondrial KATP channels and L-type Ca²⁺ channels^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female nude mice (6 weeks old, 9 per group, OVCAR-3 cells were injected s.c. into the left flank of each mouse)^[3]
Dosage:

10 or 30 mg/kg
Administration:

Administered orally in the drinking water, initiated on day 8 of cell inoculation, daily for 4 weeks
Result:

Suppressed OVCAR-3 tumor growth in these female nude mice, and reduced microvessel density.

Animal Model:

Male Balb/cAnNCrICrIj mice (8 weeks old, 23-30 g, methamphetamine (METH, 3 mg/kg) was injected subcutaneously (s.c.) in a volume of 10 ml/kg)^[2]
Dosage:

0, 10, 20, or 40 mg/kg
Administration:

IP, once, 30 min before the administration of METH
Result:

Significantly attenuated METH-induced hyperlocomotion and the development of behavioral sensitization in mice at 40 mg/kg. Did not exert any effect on the induction of METH-induced hyperthermia in mice. Significantly attenuated the reduction of DA and DOPAC in the striatum. Significantly attenuated the reduction of DAT-immunoreactivity in the mouse striatum. Significantly attenuated the increase in MAC1-immunoreactivity in the striatum after the administration of METH.

Animal Model:

Male Sprague-Dawley rats (270-330 g, TMCAO model)^[1]
Dosage:

3 mg/kg and 10 mg/kg
Administration:

IV, once, 4, 5, or 6 hours post TMCAO
Result:

Reduced infarct size by 42% while 10 mg/kg reduced infarct size by 56% at doses of 3 mg/kg; significantly reduced infarct size at 5 hours by 40% at doses of 10 mg/kg and the 3 mg/kg dose significantly reduced infarct size by 34%. With a 6 hour time window there was a non-significant trend in infarct reduction.

Animal Model:

Male Sprague-Dawley rats (270-330 g)^[1]
Dosage:

3, 10, or 20 mg/kg
Administration:

IV, once
Result:

Peak concentrations of serum levels of minocycline averaged 3.6, 13.0 and 28.8 mg/L with 3, 10 and 20 mg/kg doses respectively. The serum levels of minocycline at a 3 mg/kg dose (3.6 mg/L) were similar to that reported in humans after a standard 200 mg dose. Did not significantly affect hemodynamic and physiological variables.

Chemical Information

CAS No. 10118-90-8
Appearance Solid
Masse moléculaire 457.48
Formule C₂₃H₂₇N₃O₇
Color Light yellow to yellow
SMILES

O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])C[C@]3([H])CC4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4N(C)C)N
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (76)

All WBIHCIFELISACell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cell Stem Cell

An inducible model of human post-implantation development derived from primed and naive stem cells. [Abstract]

2025 Oct 2;32(10):1509-1527.e9. PMID: 40885193
Nat Neurosci

GABA-dependent microglial elimination of inhibitory synapses underlies neuronal hyperexcitability in epilepsy. [Abstract]

2025 Jul;28(7):1404-1417. PMID: 40425792
Adv Funct Mater

2023 Jul 7.
Nat Commun

Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]

2022 Mar 2;13(1):1116. PMID: 35236849
Theranostics

Microglia exacerbate white matter injury via complement C3/C3aR pathway after hypoperfusion. [Abstract]

2020 Jan 1;10(1):74-90. PMID: 31903107
Adv Sci (Weinh)

Microglia-Derived Interleukin-6 Triggers Astrocyte Apoptosis in the Hippocampus and Mediates Depression-Like Behavior. [Abstract]

2025 Mar;12(11):e2412556. PMID: 39888279

Minocycline purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(11):e2412556. [Abstract]

Representative images of Iba1 (green) and IL-6 (red) staining in the hippocampus of Con and CSDS mice treated with Minocycline (Mino) (40 nM, 250 nL/side) or aCSF via an infusion cannula.
Research (Wash D C)

Interleukin-4-Mediated NLRP3 Inflammasome Activation in Microglia Contributes to Allergic Rhinitis via Central Sensitization. [Abstract]

2025 Sep 25:2025:0897. PMID: 41019284
Pharmacol Res

Proinflammatory activation of microglia in the cerebellum hyperexcites Purkinje cells to trigger ataxia. [Abstract]

2023 May:191:106773. PMID: 37068531
J Neuroinflammation

The activation of hippocampus microglia in the occurrence of airway hyperresponsiveness comorbidity anxiety. [Abstract]

2025 Oct 28;22(1):249. PMID: 41152897
J Neuroinflammation

Microglia P2X4 receptor contributes to central sensitization following recurrent nitroglycerin stimulation. [Abstract]

2018 Aug 30;15(1):245. PMID: 30165876

Minocycline purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Aug 30;15(1):245. [Abstract]

Immunostaining of the trigeminal nucleus caudalis (TNC) for Iba1 in the NTG group and the NTG+Minocycline (Mino) group on day 9.
Phytomedicine

Gastrodin programs an Arg-1+ microglial phenotype in hippocampus to ameliorate depression- and anxiety-like behaviors via the Nrf2 pathway in mice. [Abstract]

2023 May:113:154725. PMID: 36867963
J Hazard Mater Adv

2025 Nov 12;20:100939.
J Headache Pain

Downregulation of neuronal DRD2 drives microglia synaptic pruning and results in cognitive deficits by promoting CCL2 release in a rat model of chronic migraine. [Abstract]

2026 Feb 9;27(1):39. PMID: 41663919
Mol Med

Formononetin ameliorates depression-like behaviors through rebalancing microglia M1/M2 polarization and inhibiting NLRP3 inflammasome: involvement of activating PPARα-mediated autophagy. [Abstract]

2025 Apr 24;31(1):153. PMID: 40275171

Minocycline purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Apr 24;31(1):153. [Abstract]

BV2 cells were pre-treated with FMN (30 µM), chloroquine (CQ, 20 µM) and minocycline (Mino, 20 µM) for 1 h and then incubated with LPS (1 µg/mL) for 24 h, quantification of protein expression levels of CD68, CD206 and NLRP3.
J Genet Genomics

Sex-biased single cell genetic landscape in mice with autism spectrum disorder. [Abstract]

2024 Mar;51(3):338-351. PMID: 37703921
Cell Rep

Microglial macrophage-derived ds-HMGB1 in DRG orchestrates neuropathic pain through immune-neural signaling. [Abstract]

2025 Dec 10;44(12):116671. PMID: 41385369
Brain Behav Immun

2026 Jul 6:138:106890. PMID: 42409183
Transl Psychiatry

Microglia-mediated inflammation and synaptic pruning contribute to sleep deprivation-induced mania in a sex-specific manner. [Abstract]

2025 Aug 15;15(1):285. PMID: 40817224
Brain Behav Immun

Microglia-mediated neurogenesis is linked to cognitive deficits in a two-hit model of maternal immune activation and juvenile stress. [Abstract]

2025 Jun 25:129:649-661. PMID: 40578538
Brain Behav Immun

Minocycline alleviates depression-like symptoms by rescuing decrease in neurogenesis in dorsal hippocampus via blocking microglia activation/phagocytosis. [Abstract]

2021 Jan:91:519-530. PMID: 33176182
Brain Behav Immun

Neuroinflammation induces anxiety- and depressive-like behavior by modulating neuronal plasticity in the basolateral amygdala. [Abstract]

2021 Jan:91:505-518. PMID: 33161163
Brain Behav Immun

Suppression of microglial activation and monocyte infiltration ameliorates cerebellar hemorrhage induced-brain injury and ataxia. [Abstract]

2020 Oct:89:400-413. PMID: 32717406
Fundam Res

Activation and polarization of striatal microglia and astrocytes are involved in bradykinesia and allodynia in early-stage parkinsonian mice. [Abstract]

2023 Jul 16;4(4):806-819. PMID: 39156564
Virulence

Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]

2026 Dec 31;17(1):2646808. PMID: 41838520
J Ethnopharmacol

Ditan Decoction ameliorates vascular dementia-induced cognitive dysfunction through anti-ferroptosis via the HIF1α pathway: Integrating network pharmacology and experimental validation. [Abstract]

2025 Mar 26:344:119459. PMID: 39978449
CNS Neurosci Ther

KCC2 Dysfunction Mediated by Microglial BDNF/TrkB Signaling Exacerbates Early Post-Stroke Seizure Susceptibility. [Abstract]

2026 Feb;32(2):e70795. PMID: 41689206
Cell Biosci

GLUT1-mediated microglial proinflammatory activation contributes to the development of stress-induced spatial learning and memory dysfunction in mice. [Abstract]

2024 Apr 16;14(1):48. PMID: 38627830
Inflamm Res

Minocycline alleviates microglia ferroptosis by inhibiting HO-1 during cerebral ischemia-reperfusion injury. [Abstract]

2024 Oct;73(10):1727-1745. PMID: 39112649

Minocycline purchased from MedChemExpress. Usage Cited in: Inflamm Res. 2024 Oct;73(10):1727-1745. [Abstract]

Minocycline (80 μM)-treated MCAO/R group was signifcantly higher than that in the MCAO/R groups.

Minocycline purchased from MedChemExpress. Usage Cited in: Inflamm Res. 2024 Oct;73(10):1727-1745. [Abstract]

ELISA results showed that Minocycline (80 μM) reduced the concentrations of TNF-α and IL-1β, and increased the concentrations of IL-4 and IL-10.

Minocycline purchased from MedChemExpress. Usage Cited in: Inflamm Res. 2024 Oct;73(10):1727-1745. [Abstract]

BV-2 cells were incubated with Minocycline (80 μM) followed by OGD/R treatment for 8 h, the LDH release assay showed cell damage.
J Neuroimmune Pharmacol

Inhibition of Microglial Activation Ameliorates Inflammation, Reduced Neurogenesis in the hippocampus, and Impaired Brain Function in a Rat Model of Bilirubin Encephalopathy. [Abstract]

2024 May 22;19(1):23. PMID: 38775885
J Clin Microbiol

Evaluation of antimicrobial susceptibility testing methods for Burkholderia cepacia complex isolates from people with and without cystic fibrosis. [Abstract]

2025 Feb 19;63(2):e0148024. PMID: 39840992
Cell Rep Methods

Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy. [Abstract]

2024 Sep 16;4(9):100843. PMID: 39216483
J Dent

Calcium phosphate cement with minocycline hydrochloride-loaded gelatine microspheres for peri-implantitis treatment. [Abstract]

2023 Sep:136:104624. PMID: 37459952
J Affect Disord

Ketamine ameliorates postpartum depression-like behaviors in rats exposed to sevoflurane during pregnancy through the AMPK/SIRT1/NLRP3 pathway. [Abstract]

2026 Jun 15:403:121439. PMID: 41698615
Eur J Pharmacol

Apoptosis-induced decline in hippocampal microglia mediates the development of depression-like behaviors in adult mice triggered by unpredictable stress during adolescence. [Abstract]

2024 Sep 5:978:176763. PMID: 38906239
Int J Mol Sci

PSMB4/MHC-I Signaling in the Cerebrospinal Fluid-Contacting Nucleus Mediates Neuroinflammatory Depression in Mice. [Abstract]

2026 May 26;27(11):4798. PMID: 42278327
Int Immunopharmacol

BDNF and NLRP3 signaling differentially regulate formation and retrieval of nitrous oxide (N2O)-related rewarding memory in dorsal hippocampus CA3 region. [Abstract]

2026 Mar 15:173:116327. PMID: 41662814
Int Immunopharmacol

Paeoniflorin attenuates neuropathic Pain-associated depression by modulating microglial M1 polarization and correcting kynurenine pathway dysregulation. [Abstract]

2025 Oct 30:164:115351. PMID: 40803216
Int Immunopharmacol

IRF8-Cathepsin S/PAR2 axis-mediated spinal microglia-neuron crosstalk is responsible for the exacerbation of postsurgical pain induced by preoperative stress. [Abstract]

2025 Aug 28:161:115034. PMID: 40482455
Int Immunopharmacol

Kaempferol improves depression-like behaviors through shifting microglia polarization and suppressing NLRP3 via tilting the balance of PPARγ and STAT1 signaling. [Abstract]

2024 Nov 3;143(Pt 3):113538. PMID: 39492132
Int Immunopharmacol

Intranasal administration of lipopolysaccharide reverses chronic stress-induced depression-like behavior in mice by microglial stimulation. [Abstract]

2023 Jul:120:110347. PMID: 37270930
Mol Neurobiol

Gut-Derived Exosomes Mediate Memory Impairment After Intestinal Ischemia/Reperfusion via Activating Microglia. [Abstract]

2021 Oct;58(10):4828-4841. PMID: 34189701
J Pathol

Hypoxia-induced regional heterogeneity in proliferative vitreoretinopathy: implications for targeted therapies. [Abstract]

2026 Jan;268(1):99-112. PMID: 41215615
Chem Biol Interact

A combined in silico and in vitro new approach methodology for early detection of liver steatogenic chemicals. [Abstract]

2026 Jul 25:435:112153. PMID: 42173389
ACS Omega

Lapatinib Acts against Biofilm Formation and the Hemolytic Activity of Staphylococcus aureus. [Abstract]

2022 Mar 3;7(10):9004-9014. PMID: 35309438
Int J Antimicrob Agents

Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. [Abstract]

2018 Aug;52(2):269-271. PMID: 29559273
Neuropharmacology

Apoptosis-triggered decline in hippocampal microglia mediates adolescent intermittent alcohol exposure-induced depression-like behaviors in mice. [Abstract]

2020 Jun 15:170:108054. PMID: 32217088
Neuropharmacology

Dynamic changes in hippocampal microglia contribute to depressive-like behavior induced by early social isolation. [Abstract]

2018 Jun:135:223-233. PMID: 29574097
J Inflamm Res

Acupuncture Activates PI3K/Akt Pathway to Promote Spinal Microglial M2 Polarization and Alleviate Spastic Hemiplegia Following Ischemic Stroke. [Abstract]

2026 Apr 17:19:592917. PMID: 42022268
Neurochem Res

2026 Jun 29;51(4):205. PMID: 42371226
iScience

Loratadine inhibits Staphylococcus aureus virulence and biofilm formation. [Abstract]

2022 Jan 5;25(2):103731. PMID: 35098100
Neurochem Res

Microglia Loss Contributes to the Development of Major Depression Induced by Different Types of Chronic Stresses. [Abstract]

2017 Oct;42(10):2698-2711. PMID: 28434164

Minocycline purchased from MedChemExpress. Usage Cited in: Neurochem Res. 2017 Oct;42(10):2698-2711. [Abstract]

a Statistical analysis showing the prevention effect of minocycline pretreatment (40 mg/kg/day) on CUS-, CRS- or CSDS-induced decreases in hippocampal microglial numbers. b, c Statistical analysis showing the prevention effect of Minocycline pretreatment (40 mg/kg/day) on CUS-, CRS- or CSDS-induced increases in the immobile time in the TST (b) and FST (c).
Ann Lab Med

In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis. [Abstract]

2021 May 1;41(3):293-301. PMID: 33303714
Neuroprotection

2026 Jul 19:10.1002/nep3.70044. PMID: 42499347
Microbiol Spectr

Eravacycline for Mycobacterium abscessus infections: pharmacodynamic advantages of long-acting post-antibiotic effects and weekly dosing regimens. [Abstract]

2026 Mar 30;14(5):e0147325. PMID: 41910138
J Clust Sci

2025 Nov 16;36(6):229.
Microbiol Spectr

Synergistic antifungal activity of minocycline as an effective augmenting agent of fluconazole against drug-resistant Candida tropicalis. [Abstract]

2025 May 6;13(5):e0318524. PMID: 40162832
Open Forum Infect Dis

Successful Treatment of Recurrent Extensively Drug-Resistant Elizabethkingia anophelis Bacteremia Secondary to Ventricular Assist Device-Associated Infection. [Abstract]

2024 Oct 11;11(11):ofae611. PMID: 39494452
Toxicol Appl Pharmacol

Minocycline attenuates the bilirubin-induced developmental neurotoxicity through the regulation of innate immunity and oxidative stress in zebrafish embryos. [Abstract]

2024 Mar:484:116859. PMID: 38342443
Brain Sci

Minocycline Attenuates Sevoflurane-Induced Postoperative Cognitive Dysfunction in Aged Mice by Suppressing Hippocampal Apoptosis and the Notch Signaling Pathway-Mediated Neuroinflammation. [Abstract]

2023 Mar 19;13(3):512. PMID: 36979321
Biochem Biophys Rep

2026 Jul 18:47:102718. PMID: 42494423
Infect Drug Resist

2026 May 8;19.
Food Chem Toxicol

Inactivation of microglia dampens blood-brain barrier permeability and loss of dopaminergic neurons in paraquat-lesioned mice. [Abstract]

2023 Apr:174:113692. PMID: 36842752
Genes (Basel)

Influence and Optimization of Diverse Culture Systems on Chicken Embryonic Stem Cell Culture. [Abstract]

2024 Oct 30;15(11):1400. PMID: 39596599
Behav Brain Res

MHC-I in the hippocampus promotes comorbid depressive symptoms in bone cancer pain via the upregulation of microglial TREM2/DAP12 signaling. [Abstract]

2024 Mar 12:461:114843. PMID: 38176616
PLoS One

Peptidoglycan recognition protein PGRP-5 is involved in immune defence and neuro-behavioral disorders in zebrafish embryos. [Abstract]

2025 Jan 31;20(1):e0315714. PMID: 39888929
Clin Exp Pharmacol Physiol

In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria. [Abstract]

2023 Jul;50(7):604-609. PMID: 37086075
J Mol Neurosci

Gamma Oscillation Disruption Induced By Microglial Activation Contributes to Perioperative Neurocognitive Disorders in Aged Mice. [Abstract]

2025 Aug 2;75(3):97. PMID: 40753364
Comput Methods Biomech Biomed Engin

Developing a diagnostic model for necroptosis in osteoporosis using bioinformatics and machine learning. [Abstract]

2025 Dec 10:1-16. PMID: 41370854
bioRxiv

2026 May 7.
SSRN

2026 Apr 7.
Res Sq

2026 Mar 9.
Research Square Preprint

2024 Mar 6.
bioRxiv

2023 Dec 20.
Research Square Preprint

2022 Feb.
Oxid Med Cell Longev

mTORC1 Activation in Chx10-Specific Tsc1 Knockout Mice Accelerates Retina Aging and Degeneration. [Abstract]

2021 Nov 5:2021:6715758. PMID: 34777691
Research Square Preprint

2020 Jun.

Solvant et solubilité

In Vitro:

DMSO : 25 mg/mL (54.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1859 mL

10.9294 mL

21.8589 mL

5 mM

0.4372 mL

2.1859 mL

4.3718 mL

10 mM

0.2186 mL

1.0929 mL

2.1859 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

All Signal Pathway Related

Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (290 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Xu L, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 2004 Apr 26;4:7. [Content Brief]

[2]. Zhang L, et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1381-93. [Content Brief]

[3]. Pourgholami MH, et al. Minocycline inhibits growth of epithelial ovarian cancer. Gynecol Oncol. 2012 May;125(2):433-40. [Content Brief]

[4]. Molina-Hernández M, et al. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):380-6. [Content Brief]

[5]. Ritchie DJ, et al. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S374-80. [Content Brief]

[6]. Ataie-Kachoie P, et al. Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. Am J Cancer Res. 2015 Jan 15;5(2):575-88. [Content Brief]

[7]. Hu X, Wu B, Wang X, Xu C, He B, Cui B, Lu Z, Jiang H. Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol. 2011 Mar 11;654(3):274-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1859 mL	10.9294 mL	21.8589 mL	54.6472 mL
	5 mM	0.4372 mL	2.1859 mL	4.3718 mL	10.9294 mL
	10 mM	0.2186 mL	1.0929 mL	2.1859 mL	5.4647 mL
	15 mM	0.1457 mL	0.7286 mL	1.4573 mL	3.6431 mL
	20 mM	0.1093 mL	0.5465 mL	1.0929 mL	2.7324 mL
	25 mM	0.0874 mL	0.4372 mL	0.8744 mL	2.1859 mL
	30 mM	0.0729 mL	0.3643 mL	0.7286 mL	1.8216 mL
	40 mM	0.0546 mL	0.2732 mL	0.5465 mL	1.3662 mL
	50 mM	0.0437 mL	0.2186 mL	0.4372 mL	1.0929 mL

Bioz

Minocycline

76 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Minocycline

Publications Citing Use of MedChemExpress (MCE) Minocycline

Voir tous les produits spécifiques à Isoform Antibiotic

Voir tous les produits spécifiques à Isoform HIF/HIF Prolyl-Hydroxylase

Voir tous les produits spécifiques à Isoform Calcium Channel